HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dennert, G. Search for Related Content PubMed Articles by Dennert, G.

Effector Mechanisms of Cell-Mediated Immunity to Xenogeneic Cell Antigens¹

From the Salk Institute for Biological Studies, the Armand Hammer Center for Cancer Biology, San Diego, California 92112

Abstract

The effector cells in mouse and rat spleen performing cell-mediated lysis of xenogeneic target cells in vitro have been identified. In mice injected with either a rat or human cell line, the cytotoxic effector cells are shown to be thymus-derived lymphocytes. Repeated challenge of mice with the human cell line also gives rise to antibody, which induces normal spleen cells to become cytotoxic, indicating that two effector mechanisms of cell-mediated lysis may operate in this model.

In the rat, cell-mediated lysis of a mouse and of a human cell line is brought about by thymus-derived lymphocytes as well as thymus independent cells, as shown by a T cell-specific antiserum. In confirmation of this, antibody, which renders normal spleen cells cytotoxic, is consistently found in the serum of rats injected with these two cell lines.

Footnotes

¹ Financial support was provided by The American Cancer Society via Grant IM 39, The Edna McConnell Clark Foundation, The Korda Foundation, and by the National Institutes of Health via Grant AI 06544 from the National Institute of Allergy and Infectious Diseases to Dr. E. S. Lennox.

² Gunther Dennert is a Fellow of The Edna McConnell Clark and The Korda Foundations.

This article has been cited by other articles:

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]